Quanterix (QTRX) Scheduled to Post Quarterly Earnings on Tuesday

Quanterix (NASDAQ:QTRX) is set to announce its earnings results after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter. Quanterix has set its FY 2024 guidance at EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Quanterix (NASDAQ:QTRX) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.05). The firm had revenue of $31.55 million during the quarter, compared to the consensus estimate of $27.92 million. Quanterix had a negative net margin of 26.42% and a negative return on equity of 9.15%. On average, analysts expect Quanterix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Quanterix Stock Up 0.6 %

QTRX opened at $17.02 on Monday. The business’s 50 day moving average is $21.81 and its 200-day moving average is $23.17. Quanterix has a twelve month low of $15.32 and a twelve month high of $29.70.

Wall Street Analysts Forecast Growth

QTRX has been the subject of a number of analyst reports. Canaccord Genuity Group reduced their price target on Quanterix from $32.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, April 29th. Scotiabank upped their price objective on shares of Quanterix from $30.00 to $32.00 and gave the stock a “sector outperform” rating in a report on Monday, March 4th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Quanterix has a consensus rating of “Buy” and an average price target of $30.60.

Insider Buying and Selling at Quanterix

In other news, Director Laurie J. Olson sold 1,500 shares of the business’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $24.35, for a total value of $36,525.00. Following the sale, the director now owns 15,238 shares of the company’s stock, valued at approximately $371,045.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.90% of the stock is currently owned by corporate insiders.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.